Digital Molecular Risk Assessment Transplant Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Digital Molecular Risk Assessment Transplant Market in 2026?

USD 858.8 million in 2026 and USD 3,887.5 million by 2036 at a 16.3% CAGR.

Demand for digital molecular risk assessment transplant services is projected to rise at 16.3% CAGR during the forecast period. Industry valuation is forecast to increase from USD 858.8 million in 2026 to USD 3,887.5 million by 2036. Transplant programs purchase these services when molecular signals guide organ-specific decisions concerning biopsy timing or immunosuppression review. HRSA reported in January 2025 that United States programs completed 48,149 organ transplants during 2024. Kidney procedures accounted for 27,759 of those transplants across a care pathway requiring long-term recipient follow-up. Commercial value improves when laboratories preserve specimen identity and return interpretable findings within the clinical decision window. Related transplant diagnostics market development shows why providers compete through report interpretation and workflow integration rather than sequencing capacity alone.

National pathways create different purchasing routes even when transplant clinicians evaluate similar molecular signals during routine care. United States centers operate within program-level outcome reporting and payer coverage decisions that reward measurable clinical utility. British laboratories work through coordinated NHS registers and public procurement structures that require service evidence across defined patient pathways. German adoption depends on regulated assays and regional service networks that support accredited molecular testing. Japanese programs require locally available products and dependable training within a transplant system facing limited donor supply. South Korean tertiary hospitals can benefit from clinical diagnostics integration, yet national payment rules and donor scarcity remain material constraints. Providers gain durable contracts by matching evidence packages with each local laboratory model and maintenance route.

Summary of the Digital Molecular Risk Assessment Transplant Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Transplant programs spend on molecular assessment when results clarify a high-consequence clinical decision across repeated care episodes. Growing transplant workloads expand the population requiring compatibility assessment and long-term graft surveillance across specialist care pathways. Blood-based testing can support earlier review without replacing biopsy or established laboratory measures across every clinical situation. Recurring protocols create steadier revenue than isolated tests because laboratories can plan collection and interpretation capacity more reliably. Commercial adoption improves through defined reimbursement and clinical responsibility across routine transplant-center ordering protocols and follow-up pathways.
Product and Segment View	The product stack combines molecular measurement with software and clinical interpretation that translate laboratory signals into defined risk categories. Next-generation sequencing is estimated to hold 31.0% share of technology in 2026, supported by broad marker coverage and scalable processing. Kidney transplant represents 30.3% of transplant type in 2026 as recipients require repeated monitoring throughout long-term follow-up. Pre-transplant risk assessment is expected to captures 38.3% in 2026 by informing candidate preparation and organ acceptance decisions. Programs must balance broader molecular coverage against bioinformatics cost and validated organ-specific interpretation requirements across supported transplant pathways.
Geography and Growth Outlook	National positions differ through regulation and reimbursement alongside service availability and transplant-center concentration within each healthcare system. Germany is projected to record 19.6% CAGR through 2036 owing to coordinated transplant infrastructure. South Korea and the United Kingdom form a close growth cluster despite different payment and procurement routes. The United States combines substantial clinical workload with uneven coverage policies that can slow recurring protocol adoption. Japan requires locally supported products and efficient small-batch services within a constrained deceased-donor environment and specialist hospital network.
Competitive Landscape	Competition separates transplant-specific surveillance services from HLA compatibility platforms and broader sequencing technologies requiring additional clinical integration. CareDx and Natera provide clinician-facing molecular reports across selected solid-organ pathways in the United States. Eurofins Transplant Genomics and Thermo Fisher Scientific combine molecular assays with interpretation support for transplant programs. Werfen and Eurobio Scientific emphasize HLA typing and laboratory workflow depth across international diagnostic networks. Illumina and QIAGEN provide enabling sequencing technologies whose commercial fit depends on specialist validation and interpretation.
Analyst Perspective	The central decision concerns whether molecular evidence changes patient management enough to justify recurring testing and added interpretation responsibility. Transplant programs must define the clinical action associated with every reported risk category before approving routine ordering. Laboratory leaders should measure turnaround and repeat-testing burden separately from analytical performance during service evaluation. Contracts need to assign responsibility for specimen logistics and borderline results alongside reimbursement support and clinician education. - Anurag Sharma, Principal Analyst at Future Market Insights

Source: FMI’s proprietary forecasting model and primary research

How is the digital molecular risk assessment transplant market segmented?

The digital molecular risk assessment transplant industry is segmented by technology, transplant type, application, end user, and region.

Technology separates sequencing and amplification methods from gene-expression or broader molecular platforms used by transplant laboratories. Transplant type classifies the organ or cell-therapy pathway responsible for each assessment requirement and follow-up schedule. Application distinguishes risk assessment before surgery from monitoring and rejection or infection surveillance following transplantation. End user identifies the organization that orders testing and carries responsibility for interpreting results during patient care. Regional analysis compares service access and regulatory conditions across established transplant systems and developing specialist laboratory networks.

What supports demand for Next-Generation Sequencing within the Technology category?

Molecular risk assessment often needs simultaneous analysis of donor and recipient markers across several assay types. NGS supports multiplex HLA typing and donor-derived cell-free DNA measurement through shared laboratory infrastructure and validated sequencing controls. In March 2026, Frontiers in Immunology published a global review comparing centralized and decentralized NGS workflows across solid-organ monitoring. Laboratory directors therefore compare sequencing breadth with validation workload and specialist interpretation responsibilities across supported organs. Related sequencing quality control market capabilities matter because failed libraries or uneven coverage can delay organ-specific decisions.

• By technology, next-generation sequencing is projected to account for 31.0% share in 2026 supported by broad marker coverage and scalable batch processing. Its position also reflects transplant laboratories that can reuse sequencing infrastructure across compatibility testing and routine post-transplant surveillance.
• Regional transplant laboratories select NGS workflows when sample volumes support trained personnel and dedicated bioinformatics review. Smaller programs often face high per-test costs and lengthy validation work, so centralized processing provides a more practical route for smaller low-volume transplant centers.

How does Kidney Transplant shape molecular assessment demand within Transplant Type?

Kidney recipients require repeated assessment because graft injury can develop across many years of clinical follow-up. Molecular tests can supplement creatinine and donor-specific antibody results during complex biopsy and treatment-review decisions. Large renal programs can establish recurring specimen routes and organ-specific interpretation protocols across specialist teams. Liquid biopsy methods gain value through documented escalation rules that connect molecular signals with clinical action.

• Kidney transplant is estimated to hold 30.3% of transplant type in 2026 owing to recipient volumes and repeated follow-up. The United Network for Organ Sharing reported in January 2026 that United States centers performed 27,573 kidney transplants during 2025. Established cell-free DNA and gene-expression services give renal programs more purchasing options than smaller organ pathways with lower testing volumes.
• Nephrologists and transplant coordinators use molecular assessment when results clarify whether changing clinical markers justify biopsy or closer surveillance. Protocol adoption remains sensitive to coverage and turnaround because isolated tests create limited value without a named response across the recipient pathway.

What makes Pre-Transplant Risk Assessment central to the Application category?

Candidate evaluation must separate immunologic risk from broader surgical suitability before an organ becomes available. Pre-transplant analysis combines HLA compatibility and molecular risk information with clinical criteria used during listing or organ acceptance. mRNA sequencing supports gene-expression discovery, but clinical transplant assays require fixed thresholds and controlled interpretation. Transplant committees need concise categories that support a named decision during short organ-allocation timelines and multidisciplinary review.

• In 2026, pre-transplant risk assessment is expected to represent 38.3% of application supported by its role in candidate preparation and donor acceptance. The segment captures recurring spending before surveillance protocols begin and carries direct consequences for multidisciplinary organ selection decisions.
• Transplant physicians adopt pre-transplant molecular assessment when conventional compatibility testing leaves important clinical uncertainty unresolved. In October 2025, the OPTN Histocompatibility Committee adopted updates to United States HLA equivalency tables used in donor and candidate matching. Programs need locally validated interpretation so additional molecular information strengthens rather than complicates multidisciplinary selection.

How do Transplant Centers evaluate molecular assessment within the End User category?

Transplant centers coordinate candidate selection and long-term follow-up across multidisciplinary clinical and diagnostic teams within specialist programs. Their operating model requires secure ordering and consistent interpretation across multiple organ programs and clinical handoffs. In July 2026, the Scientific Registry of Transplant Recipients released United States program-specific reports using OPTN data available through April 2026. Bioinformatics platforms must therefore support traceable review and program-level governance across multiple transplant services and laboratories. Borderline results create a further need for accessible clinical consultation across organ-specific treatment decisions and follow-up protocols.

• Transplant centers are likely to capture 38.8% share of end user in 2026 due to direct control over ordering and treatment decisions. Their concentrated specialist volumes also support recurring protocols that independent laboratories cannot govern across the complete patient pathway.
• Center directors approve recurring molecular testing when risk reports align with quality oversight and defined escalation rules. Implementation requires specimen logistics and formal staff training because fragmented responsibility can delay critical results across multidisciplinary organ teams and regional laboratory handoffs.

What are the drivers, restraints, and opportunities in the digital molecular risk assessment transplant market?

Growing transplant workloads support demand for repeatable molecular assessment, but biological interpretation and reimbursement restrict routine use. Integrated evidence and clinical support create a practical opening for accountable transplant pathways.

• Driver: Transplant workloads create recurring demand for risk assessment that can guide biopsy timing and treatment review.
• Restraint: Biological confounding and uncertain reimbursement limit routine testing without clear interpretation and escalation protocols.
• Opportunity: Integrated molecular evidence and clinical consultation can replace fragmented results with a governed transplant pathway.

Transplant programs face growing workloads across candidate assessment and long-term graft surveillance within specialist care pathways. Molecular services create spending when reports direct biopsy timing or treatment review within an established protocol. HRSA reported in April 2026 that more than 100,000 people were awaiting organ transplants in the United States. The waiting population increases pressure on specialist teams to protect scarce grafts and allocate clinical attention. Molecular diagnostics workflows gain recurring revenue through scheduled testing that produces a documented clinical response for each risk category.

Biological confounding limits routine adoption because elevated donor-derived cell-free DNA does not identify rejection by itself. Infection and ischemic injury can produce similar signals that require interpretation beside established clinical findings. In September 2025, Clinical Transplantation and Research published a global review documenting technical and biological factors affecting dd-cfDNA interpretation across solid-organ transplantation. Laboratories need validated exception rules and confirmatory pathways before programs can rely on recurring testing. Coverage uncertainty adds a separate barrier to preferred testing schedules across participating transplant programs and payer networks.

Integrated evidence creates an opening for services that combine molecular measurement with organ-specific interpretation and clinical consultation. Transplant teams can use that model to select biopsies more precisely and manage discordant conventional findings. The American Journal of Transplantation published a United States multicenter analysis in December 2025 covering 1,070 kidney biopsies and improved rejection yield. Providers can capture the opening by embedding clinical NGS analysis within documented escalation pathways and service agreements. Commercial value depends on proving that results change care rather than adding another laboratory output.

Which country CAGRs are profiled in the digital molecular risk assessment transplant market?

Country	CAGR
USA	15.5%
UK	17.7%
Germany	19.6%
Japan	15.3%
South Korea	18.0%

How do country-level CAGRs compare in the digital molecular risk assessment transplant market?

The country CAGRs span 4.3 percentage points between Japan and Germany across the modeled period. The United Kingdom and South Korea form a close upper cluster separated by 0.3 percentage points. The United States and Japan create a lower pair with a narrow 0.2-point difference. Germany remains 1.6 points above South Korea and sits outside both compressed national clusters. Country positions reflect service access and pathway readiness rather than current market size or installed capacity.

• Germany remains separated from the upper cluster through coordinated transplant structures and regulated laboratory capacity that supports formal pathway development.
• The United Kingdom benefits from centralized healthcare purchasing but public procurement can lengthen evaluation during formal national service reviews.
• South Korea combines tertiary-care concentration with advanced laboratories but donor shortages can restrict recurring molecular testing across eligible recipients.
• The United States combines a large transplant workload with established programs but fragmented payer policies produce uneven recurring testing protocols.
• Japan combines disciplined specialist pathways with limited donor availability as regulatory status and distributor support shape practical commercial access.

Comparable CAGRs can therefore produce different entry conditions across reimbursement systems and laboratory service models. Companies must assess training capacity and maintenance routes before treating forecast proximity as equivalent commercial access. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• United States transplant programs operate under federal data submission and outcome requirements that shape clinical governance. The United States digital molecular risk assessment transplant market is projected to grow at 15.5% CAGR through 2036 supported by a large network of accountable centers. CMS confirmed in October 2024 that initial Medicare transplant-program approval requires data submission and clinical experience alongside outcome compliance in the United States. Federal oversight favors services that document decision utility within established quality processes and program accountability requirements. Coverage differences across public and private payers remain a material friction for recurring molecular testing protocols. Providers need billing support and HLA typing integration that fits each center’s laboratory model and care pathway.
• United Kingdom transplant services use national registers and NHS pathways for organ allocation and follow-up. United Kingdom demand for digital molecular risk assessment transplant services is forecast at 17.7% CAGR through 2036 through coordinated governance. National coordination concentrates evidence review and sample routing across specialist centers under shared clinical governance. NHS Blood and Transplant reported in May 2026 that more than 8,200 candidates remained active in the United Kingdom. The organization recorded almost 4,000 transplants during the preceding year across the national service network. Public procurement remains a material friction for recurring molecular tests without demonstrated budget and service impact. Providers need local sample logistics and training that support consistent escalation across NHS transplant units.
• Germany coordinates deceased organ donation through the DSO and seven service regions that support hospitals across the country. Germany is estimated to post 19.6% CAGR through 2036 supported by coordinated clinical infrastructure. In April 2026, the DSO published its 2025 national report covering the complete donation pathway and regional hospital support across Germany. Regional coordination enables standardized sample routes and training across specialist networks in seven established service areas. European in vitro diagnostic requirements create a material friction for assays lacking appropriate status or local evidence. Distributors need German-language support and dependable maintenance across each service region for routine laboratory deployment.
• Japan’s nationally coordinated registration system concentrates transplant care within a limited deceased-donor pathway and specialized hospital network. Adoption of digital molecular risk assessment transplant services in Japan is estimated to expand at 15.3% CAGR during the forecast period owing to disciplined specialist practice. Scarce organs increase the value of careful recipient assessment and coordinated graft surveillance across specialized hospitals. Japan Organ Transplant Network listed 14,983 kidney transplant candidates across Japan in June 2026. Small procedure batches remain a material friction for local laboratory economics and sequencing utilization across hospitals. Providers need Japanese regulatory support and clinician training that allow molecular results to complement established markers across specialized centers.
• South Korea combines tertiary hospital concentration with a reform plan for donation and transplant coordination. The South Korean digital molecular risk assessment transplant industry is projected to record 18.0% CAGR through 2036 supported by stronger institutional coordination. The South Korean government reported in February 2026 that 54,789 people were awaiting transplantation nationwide. The same release recorded 370 deceased donors during 2025 and introduced the national plan covering 2026 through 2030. Hospital concentration enables centralized training and service delivery across major tertiary transplant programs in South Korea. Donor scarcity remains a material friction because limited transplant activity restricts recurring assessment episodes within hospitals. Providers need local clinical evidence and payment partnerships before broad protocol adoption across tertiary hospital networks.

Who are the notable companies in the digital molecular risk assessment transplant market?

CareDx, Natera, Eurofins Transplant Genomics, Thermo Fisher Scientific, Werfen, Eurobio Scientific, Illumina, and QIAGEN are notable companies shaping this market.

Competition combines transplant-specific laboratory services with compatibility platforms and broader sequencing technologies inside regulated clinical pathways. CareDx and Natera provide clinician-facing donor-derived cell-free DNA services across selected solid-organ programs in the United States. Eurofins Transplant Genomics and Thermo Fisher Scientific combine molecular assays with organ-specific interpretation support across kidney and other transplant programs. Werfen and Eurobio Scientific focus more strongly on HLA typing and laboratory workflow tools across regulated diagnostic settings. Illumina and QIAGEN provide enabling NGS platforms that require transplant-specific validation before routine clinical use. Experience in molecular point-of-care testing can support decentralized specimen handling, although interpretation remains concentrated within specialist centers.

• CareDx and Natera compete alongside Eurofins Transplant Genomics through donor-derived cell-free DNA or gene-expression services across solid-organ programs. Transplant programs compare organ coverage and report interpretation before selecting a recurring surveillance partner under long-term service contracts.
• Thermo Fisher Scientific and Werfen support broader laboratory workflows alongside Eurobio Scientific through molecular biopsy assessment or HLA testing. Their commercial fit depends on instrument compatibility and dependable technical service across distributed hospital laboratories that require locally authorized products.
• Illumina and QIAGEN provide sequencing chemistry or analytical tools that enable specialized transplant workflows across research and clinical laboratories. Their platforms require assay design and external clinical interpretation before becoming complete risk-assessment offerings for transplant programs. Purchasing decisions therefore emphasize local bioinformatics expertise and validated assay governance across intended clinical applications.

Competitive Benchmarking: Digital Molecular Risk Assessment Transplant Market

Company	Molecular Surveillance	HLA and Compatibility Testing	Clinical Interpretation Support	Geographic Reach
CareDx	High	Low	High	United States
Natera	High	Low	High	United States
Eurofins Transplant Genomics	High	Low	High	United States
Thermo Fisher Scientific	High	High	High	Global
Werfen	Low	High	Medium	Global
Eurobio Scientific	Medium	High	Medium	Europe and selected global markets
Illumina	Low	Medium	Low	Global
QIAGEN	Low	Medium	Low	Global

Scoring evaluates each capability independently through current official product evidence and documented commercial availability within transplant workflows. Molecular Surveillance receives High for dedicated organ-specific services; Medium applies to narrower monitoring support; Low reflects documented enabling technologies outside routine surveillance. HLA and Compatibility Testing receives High for broad typing portfolios; Medium applies to enabling analysis tools; Low reflects portfolios focused outside direct matching. Clinical Interpretation Support receives High for integrated risk reporting; Medium applies to partial workflow guidance; Low reflects platform output without transplant-specific interpretation.

Key Developments in the Digital Molecular Risk Assessment Transplant Market

• In June 2026, CareDx completed the sale of its Lab Products business to Eurobio Scientific following Swedish regulatory clearance. The transaction transferred rapid donor HLA kits and NGS transplant typing products while moving NGS monitoring assays outside North America. CareDx retained its United States testing services and digital solutions, which separates service ownership from product ownership under the current corporate structure.
• In June 2024, Natera launched Donor Quantity Score within Prospera Heart to supplement the traditional donor-derived cell-free DNA fraction. Natera reported that the two-threshold method improved sensitivity and specificity in an initial analysis of 703 plasma samples. The development gives heart transplant teams another metric for evaluating rejection risk when background cell-free DNA changes independently from graft health.
• In October 2024, Werfen completed its acquisition of Omixon after receiving regulatory and antitrust approvals. The transaction added NGS transplant diagnostics and expanded Werfen’s HLA portfolio for hospitals and clinical laboratories. Werfen stated that Omixon served more than 60 laboratories through its typing portfolio, and the completed deal removed Omixon from the independent company roster.
• In July 2025, QIAGEN launched QIAseq xHYB Long Read Panels for complex genomic regions including HLA typing. The panels combine long-read target enrichment with bioinformatics and give transplant laboratories another option for difficult HLA regions within research workflows. Clinical adoption requires validated local protocols and appropriate regulatory status within every intended commercial geography.

Key Players in the Digital Molecular Risk Assessment Transplant Market

Transplant Molecular Surveillance Providers

• CareDx
• Natera
• Eurofins Transplant Genomics
• Thermo Fisher Scientific

HLA and Compatibility Testing Providers

• Werfen
• Eurobio Scientific

Sequencing and Bioinformatics Enablers

• Illumina
• QIAGEN

Digital Molecular Risk Assessment Transplant Market - Report Scope

Coverage field	Report scope
Market breakdown	Technology, Transplant Type, Application, End User, and region.
Quantitative Units	USD million.
Market Definition	Digital molecular tests and analytical services used to assess compatibility, rejection risk, infection risk, or graft injury across transplant pathways.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	USA, UK, Germany, Japan, and South Korea.
Key Companies Profiled	CareDx, Natera, Eurofins Transplant Genomics, Thermo Fisher Scientific, Werfen, Eurobio Scientific, Illumina, and QIAGEN.
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing supported by primary interviews and official desk research.

Digital Molecular Risk Assessment Transplant Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Digital Molecular Risk Assessment Transplant Market by Segments

Digital Molecular Risk Assessment Transplant Market segmented by Technology:

• Next-Generation Sequencing (NGS)
• Digital PCR
• Gene Expression Profiling
• Molecular Diagnostics Platforms

Digital Molecular Risk Assessment Transplant Market segmented by Transplant Type:

• Kidney Transplant
• Liver Transplant
• Heart Transplant
• Lung Transplant
• Hematopoietic Stem Cell Transplant

Digital Molecular Risk Assessment Transplant Market segmented by Application:

• Pre-Transplant Risk Assessment
• Post-Transplant Monitoring
• Rejection Surveillance
• Infection Risk Assessment

Digital Molecular Risk Assessment Transplant Market segmented by End User:

• Transplant Centers
• Hospitals
• Diagnostic Laboratories
• Research Institutes

Digital Molecular Risk Assessment Transplant Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• Health Resources and Services Administration. (2025, January 15). Organ Transplants Exceeded 48,000 in 2024; a 3.3 Percent Increase From the Transplants Performed in 2023.
• Sairafi, D., Foord, E., Pettersson, L., & Uhlin, M. (2026, March 6). Advances in donor-derived cell-free DNA monitoring for solid organ transplantation. Frontiers in Immunology, 17, Article 1769036.
• United Network for Organ Sharing. (2026, January 28). USA surpasses 49,000 organ transplants while deceased organ donations dip.
• Health Resources and Services Administration. (2025, October 14). 2025 Histocompatibility HLA Table Update.
• Scientific Registry of Transplant Recipients. (2026, July 7). Technical Methods for the Program-Specific Reports.
• Health Resources and Services Administration. (2026, April 1). HRSA Honors National Donate Life Month, Advances Organ Transplant System Modernization.
• Kang, H., Cho, S.-I., & Oh, E.-J. (2025, September 8). Donor-derived cell-free DNA in solid organ transplantation: analytical considerations, diagnostic performance, and clinical interpretation. Clinical Transplantation and Research, 39(3), 200-213.
• Bromberg, J. S., Brennan, D. C., Taber, D. J., Cooper, M., Anand, S., Akalin, E., Huang, E., Klein, J. A., Glehn-Ponsirenas, R., Rogers, J., Chuang, P., Kothari, A. S., Shen, L., Woodward, R. N., Kumar, D., Wojciechowski, D., Mandelbrot, D., Costa, N., Bu, L., & Weir, M. R. (2025, December). Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies. American Journal of Transplantation, 25(12), 2529-2542.
• Centers for Medicare & Medicaid Services. (2024, October 10). Outcome Requirements for Initial Transplant Program Approval.
• NHS Blood and Transplant. (2026, May 21). First national digital organ donation drive of its kind released to NHS App users in England.
• Deutsche Stiftung Organtransplantation. (2026, April 21). Jahresbericht 2025 der Deutschen Stiftung Organtransplantation (DSO) erschienen [2025 annual report of the German Organ Transplantation Foundation published].
• Japan Organ Transplant Network. (2026, June 30). [Number of registered transplant candidates].
• Lee, G.-H. (2026, February 26). [Expanding the foundation for life sharing as 50,000 await organ transplants].
• Natera. (n.d.). Blood Test for Kidney Transplant Rejection -Prospera.
• Eurofins Transplant Genomics. (n.d.). Improving Transplant Recipient Outcomes.
• Thermo Fisher Scientific. (n.d.). MMDx for Molecular Biopsy Assessment.
• Werfen. (n.d.). Werfen | Leading Provider Of Transfusion & Transplantation Diagnostic Products Worldwide.
• Eurobio Scientific. (n.d.). Transplantation -Eurobio Scientific | Diagnostics & Oncology.
• QIAGEN. (n.d.). QIAseq xHYB Long Read Panels for complex genomic analysis.
• CareDx. (2026, June 30). CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific.
• Natera. (2024, June 17). Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients.
• Werfen. (2024, October 16). Werfen acquires Omixon.
• QIAGEN. (2025, July 22). QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the digital molecular risk assessment transplant market in 2026 and 2036?
• Which clinical pressures support recurring molecular assessment across transplant pathways?
• Why does next-generation sequencing hold the main technology share in 2026?
• How does kidney transplant influence repeated molecular monitoring demand?
• Why does pre-transplant risk assessment hold a substantial application share?
• How do country growth rates differ across the USA, UK, Germany, Japan, and South Korea?
• Which companies provide molecular surveillance or compatibility-testing platforms?
• What limits interpretation and reimbursement across routine transplant protocols?
• How should transplant centers evaluate service integration and clinical support?